Market closed
DaVita/$DVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DaVita
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Ticker
$DVA
Sector
Trading on
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
76,000
Website
DaVita Metrics
BasicAdvanced
$12B
14.16
$10.73
0.99
-
Price and volume
Market cap
$12B
Beta
0.99
52-week high
$179.60
52-week low
$125.64
Average daily volume
1M
Financial strength
Current ratio
1.26
Quick ratio
1.145
Long term debt to equity
544.412
Total debt to equity
576.988
Interest coverage (TTM)
3.70%
Management effectiveness
Return on assets (TTM)
7.15%
Return on equity (TTM)
51.74%
Valuation
Price to earnings (TTM)
14.158
Price to revenue (TTM)
1.007
Price to book
101.01
Price to tangible book (TTM)
-1.64
Price to free cash flow (TTM)
8.803
Growth
Revenue change (TTM)
5.56%
Earnings per share change (TTM)
44.61%
3-year revenue growth (CAGR)
3.32%
3-year earnings per share growth (CAGR)
6.43%
What the Analysts think about DaVita
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for DaVita stock.
DaVita Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DaVita Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DaVita News
AllArticlesVideos
YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities
GlobeNewsWire·1 month ago
Here's why this Warren Buffett stock plunged 11% in a day
Finbold·1 month ago
DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping.
Market Watch·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for DaVita stock?
DaVita (DVA) has a market cap of $12B as of April 03, 2025.
What is the P/E ratio for DaVita stock?
The price to earnings (P/E) ratio for DaVita (DVA) stock is 14.16 as of April 03, 2025.
Does DaVita stock pay dividends?
No, DaVita (DVA) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next DaVita dividend payment date?
DaVita (DVA) stock does not pay dividends to its shareholders.
What is the beta indicator for DaVita?
DaVita (DVA) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.